Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$11.29 USD
+0.29 (2.64%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.30 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Cash flow Statements
Fiscal Year End for Amicus Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -151.58 | -236.57 | -250.46 | -276.85 | -356.39 |
Depreciation/Amortization & Depletion | 10.49 | 7.98 | 8.70 | 10.64 | 7.32 |
Net Change from Assets/Liabilities | -47.99 | -39.88 | -28.94 | -32.06 | 11.61 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 119.99 | 101.90 | 68.21 | 64.99 | 87.04 |
Net Cash From Operating Activities | -69.09 | -166.58 | -202.49 | -233.29 | -250.42 |
Property & Equipment | -7.44 | -0.36 | -3.88 | -3.23 | -20.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 105.50 | 92.67 | 82.65 | -10.35 | 115.17 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 98.06 | 92.32 | 78.76 | -13.58 | 95.15 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 85.29 | -7.18 | 214.20 | 32.25 | 198.05 |
Issuance (Repayment) of Debt | -20.96 | -0.28 | -0.48 | 230.60 | -0.42 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -2.65 | 0.00 | -1.65 | 0.00 | 19.88 |
Net Cash from Financing Activities | 61.68 | -7.46 | 212.07 | 262.86 | 217.50 |
Effect of Exchange Rate Changes | 6.31 | -14.62 | -5.05 | 3.83 | 1.73 |
Net Change In Cash & Equivalents | 96.96 | -96.34 | 83.29 | 19.82 | 63.97 |
Cash at Beginning of Period | 153.12 | 249.46 | 166.16 | 146.34 | 82.38 |
Cash at End of Period | 250.08 | 153.12 | 249.46 | 166.16 | 146.34 |
Diluted Net EPS | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 |
Fiscal Year End for Amicus Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -64.12 | -48.42 | -151.58 | -117.74 | -96.16 |
Depreciation/Amortization & Depletion | 5.43 | 2.69 | 10.49 | 7.77 | 4.82 |
Net Change from Assets/Liabilities | -11.23 | -22.32 | -47.99 | -48.69 | -15.94 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 62.91 | 38.36 | 119.99 | 86.11 | 73.08 |
Net Cash From Operating Activities | -7.00 | -29.70 | -69.09 | -72.55 | -34.20 |
Property & Equipment | -2.91 | -1.81 | -7.44 | -5.71 | -4.14 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -11.53 | 9.35 | 105.50 | 127.73 | 90.40 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -14.44 | 7.54 | 98.06 | 122.02 | 86.26 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -14.09 | -13.27 | 85.29 | 54.61 | 16.96 |
Issuance (Repayment) of Debt | -0.08 | -0.04 | -20.96 | -0.08 | -0.05 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -2.65 | -1.06 | -1.06 |
Net Cash from Financing Activities | -14.17 | -13.31 | 61.68 | 53.47 | 15.85 |
Effect of Exchange Rate Changes | -2.11 | -1.82 | 6.31 | 10.22 | -6.68 |
Net Change In Cash & Equivalents | -37.72 | -37.28 | 96.96 | 113.16 | 61.22 |
Cash at Beginning of Period | 250.08 | 250.08 | 153.12 | 153.12 | 153.12 |
Cash at End of Period | 212.36 | 212.79 | 250.08 | 266.27 | 214.33 |
Diluted Net EPS | -0.05 | -0.16 | -0.11 | -0.07 | -0.15 |